Key statistics
As of last trade Eledon Pharmaceuticals Inc (ELDN:NAQ) traded at 2.55, -23.86% below its 52-week high of 3.35, set on May 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.51 |
---|---|
High | 2.65 |
Low | 2.48 |
Bid | 2.53 |
Offer | 2.57 |
Previous close | 2.48 |
Average volume | 62.45k |
---|---|
Shares outstanding | 39.66m |
Free float | 38.30m |
P/E (TTM) | -- |
Market cap | 98.35m USD |
EPS (TTM) | -2.52 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 17:07 BST.
More ▼
- Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
- Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
- Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
- Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
- Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
- Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
- Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
- Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
- Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
- Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
More ▼